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DOI 10.1016/j.ccr.2010.08.006SUMMARYIt was previously shown that the NF-kB pathway is downstream of oncogenic Notch1 in T cell acute
lymphoblastic leukemia (T-ALL). Here, we visualize Notch-induced NF-kB activation using both human
T-ALL cell lines and animal models. We demonstrate that Hes1, a canonical Notch target and transcriptional
repressor, is responsible for sustaining IKK activation in T-ALL. Hes1 exerts its effects by repressing the
deubiquitinase CYLD, a negative IKK complex regulator. CYLD expression was found to be significantly
suppressed in primary T-ALL. Finally, we demonstrate that IKK inhibition is a promising option for the
targeted therapy of T-ALL as specific suppression of IKK expression and function affected both the survival
of human T-ALL cells and the maintenance of the disease in vivo.INTRODUCTION
NF-kB is an important regulator of cell survival, proliferation and
differentiation and is frequently involved in malignant transfor-
mation (Karin, 2006). NF-kB is mainly activated in response to
proinflammatory stimuli such as TNFa or IL1b, components
of pathogenic bacteria and viruses, or after TCR signaling in
T-lymphocytes. Regardless of the activation of specific recep-
tors that associate to different effectors, canonical NF-kB
signaling invariably leads to the activation of IkB kinase (IKK)Significance
Although aberrant activation of the Notch pathway is a recurr
activation are poorly defined. Our work demonstrates that the
of leukemia, and that blocking NF-kB (or the IKK kinase) is su
mutations. These findings suggest that NF-kB targeting could b
268 Cancer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier Incomplex composed by two catalytic and one regulatory subunits
called IKKa, IKKb, and NEMO (IKKg), respectively. The main
target of activated IKK complex is the NF-kB inhibitor, IkB, that
it is rapidly phosphorylated in specific serine residues thus
targeting the protein for ubiquitination, leading to proteasomal
degradation. Degradation of IkB is sufficient to induce the
nuclear translocation of the transcription factor that results in
specific gene activation (Vallabhapurapu and Karin, 2009). IkBa
itself is one of the main transcriptional targets for NF-kB activity
thus providing an efficient mechanism for signal terminationing event in T-ALL, the downstream signaling effects of this
Notch-Hes1-CYLD-IKK axis plays a crucial role in this type
fficient to eliminate leukemic cells carrying activating Notch
e a key component of successful future T-ALL clinical trials.
c.
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Notch-Induced Hes1 Represses CYLD in T-ALL(Hoffmann et al., 2002). However, other mechanisms are
required to maintain the nonactive state of NF-kB in the absence
of stimulation but also to attenuate the signal after chronic
stimulation of the pathway. They involve the deubiquitination
enzymes A20 and CYLD, which remove the activator K63 ubiq-
uitin chains from different elements of the NF-kB signalosome
(Brummelkamp et al., 2003; Reiley et al., 2007; Trompouki
et al., 2003; Wertz et al., 2004).
Despite the huge amount of gathered data on NF-kB activa-
tion, not much is known about the crosstalk of NF-kB with other
signaling pathways, including pathways that control tissue
differentiation like the Notch cascade. Notch receptors are
crucial regulators of cell differentiation in multiple systems
(reviewed by Egan et al., 1998). Activation of Notch by Jagged
or Delta ligands results in the cleavage of the intracellular frag-
ment of the receptor by a g-secretase activity (Mumm et al.,
2000). Once released from the extracellular part of the molecule,
the intracellular cleaved Notch translocates to the nucleus to
bind the ubiquitous RBPjk factor and to activate transcription
of a number of target genes, including the Hes family of
transcription factors (Iso et al., 2003; Jarriault et al., 1995). The
classical function of Hes family proteins is the transcriptional
repression of prodifferentiation genes by direct interaction with
specific sequences of their promoters or by the association
with other bHLH factors and combinatorial DNA binding
(Kageyama and Ohtsuka, 1999; Kuroda et al., 1999). The Notch
pathway was recently shown to be oncogenic in a wide variety of
cancers, most notably in T cell acute lymphoblastic leukemia
(T-ALL), a devastating pediatric tumor arising by the transforma-
tion of hematopoietic progenitor cells. In this disease, the
majority of patients harbor either activating mutations of Notch1
or inactivating mutations affecting negative regulators of the
Notch pathway (Aifantis et al., 2008).
Recent evidence has suggested an interaction between Notch
andNF-kB,more specifically in the context of cell transformation.
Crosstalk between the Notch and NF-kB pathways have been
proposed in humanT-ALLand inmousemodels of T cell leukemia
(Screpanti et al., 2003; Shin et al., 2006; Vilimas et al., 2007).
More specifically, we have previously shown that Notch activa-
tion can induce the expression of a large fraction of classical
NF-kB gene targets in T cell progenitors. We have also demon-
strated that this Notch-induced NF-kB activation requires both
the transcriptional activity of Notch and the function of the IKK
complex (Vilimas et al., 2007). However, these studies failed to
provide a definitive demonstration that this interaction can be
translated into a new therapeutic tool. Moreover, neither the
mechanism explaining the ability of Notch to impinge on IKK
(and thus NF-kB) activation nor the importance of IKK activation
for the maintenance of T-ALL in vivo was addressed. These key
issues could introduce NF-kB inhibition as an effective therapy
for the treatment of T-ALL and are all addressed here.
RESULTS
Oncogenic Notch Induces NF-kB Activation both In Vitro
and In Vivo
We attempted to visualize in vivo the Notch-induced NF-kB
activation using an animal model of T-ALL. We combined an
established transplantation model with a NF-kB-dependentCanin vivo luciferase reporter strain (kBLuc) to measure the activa-
tion of this pathway. We transplanted ICN1+kBLuc+ progenitors
in irradiated hosts and monitored the progression of the disease
and the activation of the reporter using both FACS analysis and
in vivo bioluminescence. Disease was induced as evidenced by
the appearance of leukemic CD4+CD8+ blast cells in the periph-
eral blood (not shown). Early during T-ALL, visual induction of
NF-kB activation was undetectable, probably due to the low
number of transformed cells at this stage of the disease.
However, NF-kB activity increased rapidly and was readily
detectable 3 weeks post-cell transplantation with ‘‘hotspots’’ in
tissues containing lymphoid cells, including the thymus and
bone marrow areas (Figure 1A).
To further prove that Notch was responsible for induction of
NF-kB activation, we used a distinct, recently generated animal
model of the disease that does not require transplantation. In this
model, the oncogenic ICN1 mutant is ‘‘knocked-in’’ the EF1a
locus and induced by Cre-recombinase expression (Buonamici
et al., 2009). ICN1 expression rapidly induced T-ALL (Figure 1B)
that overexpressed nuclear Notch1-IC and its target gene Hes1
(Figures 1C and 1D). To test whether NF-kB was activated in the
leukemic cells, we sorted the CD4+CD8+ population and used
a conventional EMSA approach. As shown in Figure 1E, this
leukemic population showed significant NF-kB activation, as
indicated by the increased DNA-binding activity. Antibody shift
experiments demonstrated a predominance of p50-p50
(Nfkb1:Nfkb1) and p50:p65 (Nfkb1:RelA) dimers.
To support that Notch is responsible for promoting NF-kB
activity in T-ALL cells, we measured the activation of a virally-
driven NF-kB-dependent EGFP reporter in a representative
human cell line (KOPT-K) that carries Notch mutations (O’Neil
et al., 2007). We either kept the cells untreated or treated them
with gamma-secretase inhibitors (GSI). Inhibition of the Notch
pathway by GSI reduced the activation of the NF-kB-dependent
EGFP reporter, the expression of the Notch-target genes Hes1,
Deltex1, the NF-kB target Bcl2A1, as well as NF-kBDNA binding
activity (Figures S1A–S1C).
These combined experiments support the hypothesis that
NF-kB is targeted by Notch and demonstrate that this crosstalk
between the two pathways takes place also in in vivo models
of T-ALL. We were thus curious to see whether this in vivo
Notch-induced NF-kB activation leads to the activation of
a subset of genes that have been characterized as direct or indi-
rect NF-kB targets. We have thus carried out a meta-analysis of
the transcriptional profiling comparisons between ‘‘control’’ and
‘‘leukemic’’ T cells carried out by Li et al. (2008). As shown in
Figure 1F, a large number of know NF-kB target genes, as
proposed by multiple studies, were significantly induced in the
CD4+8+Notch1-IC+ tumor samples. To further identify genes
induced in leukemia that are direct NF-kB targets, we have
combined our analysis to a recent report that combined whole-
genome chromatin immunoprecipitation data (ChIP-seq) and
RNA-sequencing data, identifying NF-kB p65 direct transcrip-
tional targets (Kasowski et al., 2010). As shown in Figure S1D
available online, we identified a significant number of NF-kB
direct targets that are significantly upregulated in T-ALL cells.
The combination of these data strongly suggest that a NF-kB
gene expression ‘‘signature’’ is characterizing leukemic T cells
in Notch-induced T-ALL.cer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier Inc. 269
Figure 1. Oncogenic Notch Induces NF-kB Activation in T-ALL Animal Models
(A) NF-kB luciferase reporter activity was detected in mice transplanted with ICN1-GFP (wt), ICN1-GFP (NFkB-ER-luc), or GFP (NFkB-ER-luc). Bioluminescent
imaging of mice 9 and 21 days after transplantation is shown.
(B) Peripheral blood CD4/CD8 FACS analysis.
(C) qRT-PCR from sorted cells as indicated. Error bars denote ± standard deviation.
(D) Protein levels of Notch1-IC (ICN1) and Lamin A/C in nuclear extracts of thymocytes fromMx-Cre (Mx) and Ef1a-ICN1, Mx-Cre (ICN1) mice 4 weeks after pIpC
injection.
(E) NF-kB DNA binding activity was analyzed by EMSA using nuclear extracts of thymocytes from MxCre, Ef1a-ICN1 Mx-Cre mice 4 weeks after pIpC injection
and wt thymocytes either untreated (Co) or treated with mTNFa.
(F) Heat map shows expression of NF-kB target genes selected from the literature (http://www.nf-kb.org) upregulated in leukemic DP cells compared to control
thymic DP cells by unpaired one-side t test with a = 0.05.
See also Figure S1.
Cancer Cell
Notch-Induced Hes1 Represses CYLD in T-ALLHes1 Induces NF-kB Activity and Nuclear Translocation
of p65 by Facilitating IkBa Degradation
Next, we addressed the mechanism of Notch-induced NF-kB
activation. To answer this question, we measured the activity
of a NF-kB-dependent reporter in response to ectopic expres-
sion of ICN1 or its main target Hes1. We found that ectopic
expression of doxycycline-inducible Hes1 (Figure 2A) or nonin-270 Cancer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier Inducible flag-Hes1 resulted in a dose-dependent activation of
NF-kB, comparable to that induced by ICN1 (Figure S2). Activa-
tion of NF-kB was concomitant with the nuclear accumulation of
p65 in Hes1 expressing cells, as detected by immunofluores-
cence (Figure 2B).
We analyzed whether modification of the IkBa protein levels
were responsible for the increased NF-kB-transcriptional activityc.
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Figure 2. Hes1 Enhances NF-kB-Dependent Activity by Inducing IkBa Degradation
(A) Luciferase assay with the 3xkB-luc-reporter in HEK293T cells transfected with a doxycycline-inducible Hes1 construct. Induction of Hes1 after doxycycline
treatment is shown in the lower panel.
(B) Immunofluorescence of HEK293T transfected with flag-Hes1 showing the expression pattern of transfected Hes1 and endogenous p65.
(C) Western blot of endogenous IkBa in HEK293T cells transfected with inducible Hes1 in the presence or absence of TNFa.
(D) Lack of IkBa immunostaining in cells transfected with ectopic Hes1.
(E) Quantitative RT-PCR to determine the expression levels of IkBa mRNA in the presence or absence of Hes1. Error bars denote ± standard deviation.
(F) Western blot of IkBa levels in HEK293T transfected with the doxycycline-inducible Hes1 construct in the presence or absence of the proteasome inhibitor
MG132.
(G) Western blot showing the levels of IkBawt or IkBaK21–22R cotransfected with inducible Hes1.
See also Figure S2.
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Notch-Induced Hes1 Represses CYLD in T-ALLinduced by Hes1. We found that ectopic Hes1 expression
correlated with a reduction in IkBa protein levels in the absence
of stimulation that was further enhanced by chronic TNFa treat-
ment (Figure 2C). Most importantly, IF staining of HEK293T cells
demonstrated that after TNFa treatment there was a complete
absence of endogenous IkBa in cells expressing ectopic Hes1,
whereas the rest of the cells have already resynthesized IkBa
(Figure 2D).
As Hes1 is a well-characterized transcriptional repressor (Iso
et al., 2003), we speculated that Hes1 was regulating IkBa at
the level of transcription. To test this possibility, we carried out
qRT-PCR from cells transfected with the control vector or the
inducible Hes1 construct, untreated or treated with TNFa and/
or doxycycline as indicated. We found that Hes1 expression did
not exert any inhibitory effect on either basal or TNFa-induced
IkBa transcription, but rather increased IkBa transcription as it
is an NF-kB target (Figure 2E). These results suggested that
Hes1 was modulating IkBa protein stability. In agreement with
this, incubation with the proteasomal inhibitor MG132 or muta-
tion of lysines 21 and 22 of IkBa into arginine, which are required
for K48-linked ubiquitination (Rodriguez et al., 1996), completely
abrogated the effects of Hes1 on IkBa levels (Figure 2F and 2G).
These results demonstrated that Hes1 is able to induce IkBa
degradation, which results in increased NF-kB activity.CanHes1 Facilitates IkBa Degradation by Modifying IKK
Activity
As it is well established that IkBa degradation is regulated by the
IKK complex, in response to the specific phosphorylation by
IKKb, we tested the effect of the IKKb inhibitor BAY65-5811 on
Hes1-induced degradation of IkBa. Inhibition of the IKK activity
completely blocked the phosphorylation of IKK and the degrada-
tion of IkBa induced by ectopic expression of Hes1 in the pres-
ence of chronic TNFa treatment (as detected with the specific
antibody recognizing phosphorylated serines 180 and 181 of
IKKa and IKKb respectively) (Figure 3A). Next, we tested whether
hes1 expression affected the phosphorylation/activation status
of IKKa or b that are the catalytic subunits of the IKK complex.
Figure 3B shows that doxycycline-inducible Hes1 expression
significantly and specifically increased the amounts of active/
phosphorylated HA-IKKb but not HA-IKKa. As a control we
show that this effect was not induced by doxycycline alone
(Figure S3A). To further demonstrate the requirement of IKKb
in the Hes1-induced degradation of IkBa, we expressed HA-
IkBa together with the inducibleHes1 construct in IKKb-deficient
MEFs. As shown in Figure 3C, Hes1 was not sufficient to induce
IkBa degradation in cells lacking IKKb, whereas reintroduction
of IKKb restored the ability of Hes1 to reduce IkBa levels.
Finally, ectopic expression of the dominant negative form ofcer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier Inc. 271
Figure 3. Hes1 Facilitates IkBaDegradation
by Regulating IKKb Activity
Western blots of cells transfected with an induc-
ible Hes1 vector and treated for 16 hr with
doxycycline and TNFa as indicated.
(A) HEK293T cells were treated with the IKK
inhibitor BAY65-1185.
(B) Cells were cotransfected with HA-IKKa or
HA-IKKb.
(C) IKKb-deficient cells were reconstituted with
HA-IKKb.
(D) HEK293T cells were transfected with the
dominant negative TAK1 (K63W) construct.
See also Figure S3.
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Notch-Induced Hes1 Represses CYLD in T-ALLTAK1 (TAK1K63W), the specific kinase that activates IKKb,
was sufficient to block the IkBa-degradation imposed by
Hes1 (Figure 3D). These results indicate that Hes1 induces
IkBa degradation by facilitating the activation of the IKK com-
plex in both basal conditions and after TNFa treatment, and
that this effect takes place upstream of IKKb phosphorylation
by TAK1.
Hes1 Is Responsible for Sustaining IKK/NF-kB Activity
in Notch-Dependent Leukemia
Based on these results, we speculated that the NF-kB activation
that occurs in T-ALL with aberrant Notch activity might be medi-
ated through Hes1. We confirmed that Notch1 activation (as de-
tected by the Val1744 antibody) was mainly, although not exclu-
sively, found in T-ALL lines, inversely correlating with the protein
levels of IkBa (Figure S3B). To determine the contribution of
Hes1 to the regulation of IkBa in T-ALL, we infected Jurkat cells
with a lentiviral construct containing the shRNA against Hes1 or
the control shRNA. Hes1 knockdown resulted in increased IkBa
levels in noninduced cells and evenmore significant after chronic
TNFa treatment (Figure 4A). Comparable results were obtained
by inhibiting Notch activation in Jurkat cells with GSI
(Figure 4B). Moreover, chronic activation of the endogenous
IKK kinase complex after TNFa treatment was eliminated in cells
with reduced Hes1 expression (Figure 4C). Next, we tested
whether NF-kB activation was regulated by Hes1 in these cells
and found a reduction in the levels of several NF-kB-target genes
such as Bcl2A1 or cIAP2 by knocking down Hes1 in both Jurkat
and most important, in primary human T-ALL cells (Figures 4D
and 4E). Identical effects were obtained in Jurkat cells treated
with GSI (Figure S4A). To study the functional relevance of
Hes1 in cells containing active Notch ex vivo, we transduced
lineage-depleted bone-marrow cells with a lentiviral vector ex-
pressing the oncogenic ICN1 alone or together with the Hes1-
shRNA construct. Cells were serially plated every week and272 Cancer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier Inc.counted as an estimated measure of self-
renewal capacity (Lavau et al., 1997)
(Figure 4F). We found that ICN1-express-
ing cells exhibited a higher clonogenic
capacity than the cells coexpressing the
Hes1-shRNA as indicated by the in-
creased number of colonies in these
cultures (Figure 4G). Importantly, ICN1-
transduced progenitors were able toproduce increasing number of CD3+ cells when plated on
OP9-Dll1 stroma compared to Hes1-shRNA-expressing cells
(Figure 4H and Table S1).Moreover, in the absence of Hes1, cells
expressing ICN1 showed an elevated number of apoptotic
cells as measured by Annexin-V binding (Figure S4B) concomi-
tant with a decrease in the expression of the prosurvival genes
Bcl2A1 and cIAP2 (Figure 4I). To determine whether NF-kB
provided prosurvival signals in ICN1-transduced cells, we plated
these cells in the presence of the IKK inhibitor BAY65-5811. In
these conditions, expression of oncogenic ICN1 was not suffi-
cient to support colony and cell growth (Figure 4J).
The Expression of the Deubiquitinase CYLD
Is Suppressed in Human T-ALL
Because our results indicated that Hes1 was able to maintain
IKK complex activation in T-ALL and we mapped this function
upstream of TAK1, we tested whether the expression of the
negative regulators of IKK activity, CYLD and A20, was
decreased in human T-ALL. In this screen we included a group
of 13 healthy control samples (9 whole peripheral blood [WPB]
and 4 purified CD3+) and 33 WPB samples from T-ALL patients
containing >60% of leukemic blasts, except sample number 18
with 44% leukemic cells (for details see Table S2). Using qRT-
PCR we found that mRNA levels of both deubiquitinating
enzymes were significantly decreased in the leukemic samples
compared to the normal controls (p = 0.001 for CYLD and
p < 0.001 for A20 using Student’s t test) concomitant with a
significant increase in the expression of Hes1 (p = 0.001) (Fig-
ure 5A). Further meta-analysis of ALL gene expression data-
bases showed that CYLD levels in T-ALL are significantly lower
than in any B-ALL category (not shown). Next, we tested
whether there is an inverse correlation between Hes1 and either
CYLD or A20 genes in T-ALL by using Hes1-specific shRNA-
mediated knock-down. Reduction of Hes1 levels resulted in
a pronounced increase in the mRNA of CYLD whereas A20
Cancer Cell
Notch-Induced Hes1 Represses CYLD in T-ALLlevels remained unaffected (Figure 5B). In contrast, overexpres-
sion of Hes1 in HEK293T cells resulted in a reduction in the
levels of CYLD mRNA (Figure 5C) and protein (Figure 5D) asso-
ciated with lower levels of IkBa, being this effect more dramatic
after chronic treatment with TNFa (Figure 5D). We next tested
whether Hes1 protein levels inversely correlated with CYLD
protein levels in different T-ALL cell lines containing Notch1
mutations. As shown in Figure 5E, CYLD levels were reduced
in T-ALL cells when compared to B cell (Nalm6, RAJI, and
RPMI1783) or myeloid leukemia cell line (HL60) concomitant
with variable, but higher levels of Hes1 protein. Importantly,
inhibition of Notch1 by GSI resulted in an increase of both
protein (Figure S5) and mRNA (not shown) levels of CYLD in
these cells.The Notch Pathway Directly Controls CYLD Expression
through Hes1
These data suggested that CYLD expression is kept suppressed
in T-ALL, leading to an enhancement of IKK activity. To test
whether the Notch pathway and specifically Hes1 was directly
repressingCYLD transcription, we used the Genomatix software
to identify putative Hes1 binding sites, and found three distinct
N-box consensus sites in the promoter and 50UTR of the CYLD
gene (Figure 6A, denoted as PRO1 and PRO2). Using a con-
ventional ChIP assay in human Hes1+ T-ALL cells and a Hes1
antibody followed by PCR with specific primers flanking the
identified putative N-box sites, we were able to show that
endogenous Hes1 binds to the predicted PRO2 site in the
CYLD 50UTR (Figure 6B) and this association was lost after
Hes1 knock-down (Figure 6C) as measured by qPCR. Ectopic
expression of CYLD completely reverted the clonogenic growth
of lineage negative BM cells transduced with ICN1 whereas
downregulation of CYLD was sufficient to increase the number
of colonies in this assay (Figure 6D). Consistent with these
results, we found that ectopic expression of CYLD is sufficient
to block Notch-induced activation of an NFkB-dependent
reporter in HEK293T (Figure S6A). Moreover, the capacity to
produce CD3+ T cells by ICN1-tranduced progenitors in cocul-
ture on OP9-Dll1 stroma is partially mimicked by CylD-shRNA-
expressing cells and lost in cells coexpressing ICN1 and CYLD
(Figure 6E and Figure S6) To further support the notion that
CYLD expression in T-ALL is controlled by direct transcriptional
repression by Hes1, we have quantified CpG methylation at the
CYLD using the previously introduced human T-ALL samples.
As shown in Figure 6F, there was no evidence of promoter hyper-
methylation suggesting that it is unlikely that DNA methylation
can explain by itself the suppression of CYLD expression. These
observations suggest that suppression of CYLD enhances the
activity of the IKK kinase and the nuclear localization of NF-kB
transcription factors. To directly test this hypothesis, we have
totally eliminated CYLD expression in T-ALL using an animal
model of CYLD deficiency (Reiley et al., 2006). As shown in
Figures S6B–S6D, CYLD deletion is sufficient to significant
enhance nuclear NF-kB activity in T-ALL cells as quantified by
EMSA. All these observations strongly suggest that Hes1
sustains IKK complex activation and maintains the tumor
phenotype in T-ALL by directly repressing CYLD expression
and function.CanTargeted IKK In Vitro Silencing Affects the Growth
of Human T-ALL Lines
Our data so far suggest that targeting the IKK complex could be
effective in the treatment of T-ALL. We have shown previously
that the proteasome inhibitor bortezomib could affect T-ALL
cell line growth (Vilimas et al., 2007). As Bortezomib is not
a specific NF-kB inhibitor (Hideshima et al., 2009), we have
now tested the effects of a cell permeable peptide (NEMO
binding domain) that specifically blocks IKK by disrupting the
interaction of NEMO to IKKb (May et al., 2000) on several (total
of nine) T-ALL cell lines that have an active Notch pathway
present and exhibit NF-kB activation. These human T-ALL cells
lines harbor activating Notch1 mutations. As shown in Figure 7A,
the NBD peptide was able to efficiently inhibit nuclear NFkB
binding activity in T-ALL lines. Interestingly, silencing NF-kB
led to specific biological effects, as shown by the rapid induction
(24 hr) of apoptosis as determined by Annexin-V binding and
caspase-3 activation (Figures 7B and 7C). No effects on cell
cycle progression were noted suggesting that IKK inactivation
is predominantly affecting cell survival (not shown).
To better understand the molecular effects of IKK inhibition
in vitro we used these five T-ALL lines to study transcriptome
changes 16 hr after the addition of the NBD peptide. The initial
conclusion from these experiments is that although the response
to NBD treatment was uniform, gene expression changes were
both general and cell-line specific (Figure 7D and Figure S7A).
All five cell lines showed signs of induction of cell death charac-
terized by the upregulation of Bcl2L11 (Bim), Bik, and Foxo3, in
agreement with their apoptotic phenotype, and an inhibition of
NF-kB target genes (such asMyc,Ptpn6,Pnkp, andGpx1). Inter-
estingly, another uniform target of IKK inhibition was the Notch
pathway itself (including Hes1, Hes4, Notch1, Notch3, and
Dtx1) suggesting a mechanism of feedback inhibition. Using
qRT-PCR we have verified the NBD-dependent regulation of
several of these genes (Figure S7B). These findings suggested
that IKK signaling was essential for disease maintenance and
proposed that IKK inhibition could be a potential therapeutic
tool in T-ALL.IKK Complex Activity Is Essential for the In Vivo
Maintenance of T-ALL
One of the key questions in cancer treatment is whether thera-
peutic targeting of a single signaling pathway is sufficient to
affect tumor maintenance and progression. To address this
key question in vivo we combined the Notch-dependent
leukemia model with an inducible IKKg (Nemo) deficiency
(Mx1-cre+Nemof/f) model. Bone marrow stem and progenitor
cells purified from Mx1-cre-inducible NEMO-deficient mice
were transduced with DEN1-luciferase or EGFP-expressing
retroviruses and transplanted into irradiated recipients. Two
weeks posttransplantation, once the disease had been estab-
lished as indicated the presence of double CD4+CD8+ lympho-
cytes in the peripheral blood (Figures 8A and 8B) and the expan-
sion of the donor cells as detected by in vivo bioluminescence
(Figures 8C and 8D), Nemo expression (and thus canonical NF-
kB activation) was silenced by inducing the expression of Cre-
recombinase using polyI-polyC injections (Kuhn et al., 1995).
As shown in Figures 8B–8F, deletion of Nemo very efficientlycer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier Inc. 273
Figure 4. Inhibition of Hes1 in Cells with Active Notch1 Prevents NF-kB Activity Leading to Increased Apoptosis
(A) Jurkat cells transduced with scrambled shRNA orHes1-shRNA (80%–90% reduction in Hes1 protein levels) were analyzed for the levels of IkBa protein during
TNFa treatment.
(B) IkBa is restored in the presence of GSI (L685,458).
(C) Levels of P-IKK in control and Hes1 knockdown cells by western blot.
(D) Expression of NF-kB-target genes by qRT-PCR in Jurkat transduced with the control or Hes1-shRNA lentivirus.
(E) Primary human T-ALL leukemic cells transduced with the control or Hes1-shRNA lentivirus.
(F) Experimental design to test the contribution of Hes1- to ICN1-transduced cells.
(G–I) Primary mouse Lin bone marrow progenitors transduced with the indicated lentivirus. (G) Colonies obtained from serial replatings on methylcellulose were
counted. (H) T cell differentiation was determined by CD3 expression after 7 days in coculture on OP9-Dll1. One representative experiment out of three is shown.
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Figure 5. The Expression of CYLD, a Nega-
tive Regulator of NF-kB, Is Suppressed in
T-ALL
(A) Levels of A20, CYLD, and Hes1 mRNA in
primary samples for normal WPB (1–9), purified
normal CD3+ cells from PB (10–13), and PB from
T-ALL patients (1–33) by qRT-PCR.
(B) Analysis by qRT-PCR of CYLD or A20 levels in
cells transduced with scrambled or Hes1-shRNA.
Error bars denote ± standard deviation for (A)
and (B).
(C) Expression of CYLD and A20 measured by
qRT-PCR in HEK293T cells expressing ectopic
Hes1 untreated or treated with TNFa.
(D) Expression of CYLD and IkBa measured by
western blot in HEK293T cells expressing ectopic
Hes1 untreated or treated with TNFa.
(E) Western blot analysis of CYLD, active Notch1
and Hes1 protein levels in different leukemic cell
lines.
See also Figure S5.
Cancer Cell
Notch-Induced Hes1 Represses CYLD in T-ALLreverted disease progression as judged by both the significant
decrease in luminescence (Figures 8C and 8D) and the disap-
pearance of transformed CD4+CD8+ T cells from the peripheral
blood of the treated animals (Figures 8A and 8B) and T cell infil-
tration in the spleen and liver (Figure 8F). In agreement to the
effects of IKK inhibition on T-ALL cell lines, IKK/Nemo deletion
lead to rapid induction of leukemic cell apoptosis (Figure 8E).
Consistent with these phenotypic observations, pI-pC treated
Nemowt/wt,MxCre+-expressing animals succumbed significantly
faster than their pI-pC treated Nemof/f, MxCre+ counterparts.
However, if the treatment was not continuous, the disease was
able to relapse and eventually kill the animals (Figure 8G). To
determine whether the reappearance of the disease was due
to the expansion of a small cell population in which Nemo was
not deleted, we sorted leukemic cells, 61 days posttransplant
(approximately 40 days after the last pI-pC injection) and tested
them for the presence of Nemo. Further supporting the essential
function of IKK signaling in T-ALL leukemias, the purified cells
were bearing the ‘‘undeleted’’ NEMO allele (Figure S8A) and
showed a significant increase of NF-kB DNA-binding activity
in the nucleus (Figure S8B). These studies are the first to demon-
strate that IKK activity is essential for the maintenance of T-ALL
and open the way for inhibiting the IKK complex as a therapeutic
target for patients with already established T-ALL.(I) Expression levels of the indicated genes were tested by qRT-PCR after 2 weeks in culture.
(J) Number of colonies obtained in serial plating from ICN1 transduced cells in the presence or absence of BA
See also Figure S4.
Cancer Cell 18, 268–281, SeDISCUSSION
Our studies demonstrate that the tran-
scriptional repressor Hes1, a target of
oncogenic Notch1, is able to induce
the activation of the NF-kB pathway in
human T-ALL lines and animal models
of the disease. Moreover, they show
that IKK/NF-kB signaling is essential for
the maintenance of the disease, asT-ALL cells that are unable to activate the IKK kinase complex
rapidly enter apoptosis. As Notch1 mutations or pathway
hyper-activation are found in the vast majority of T-ALL patients,
our findings are clinically important as they could be translated
to either as single agent therapy targeting IKK (or NF-kB) activa-
tion or combinatorial drug treatments that could in parallel
target additional elements of the Notch pathway.
The presented studies identify a previously unidentified
mechanism of Notch-induced NF-kB activation in T-ALL. We
show that Hes1 is a key mediator of Notch-induced transforma-
tion by targeting the deubiquitinase CYLD, a negative regulator
of IKK activity. Our experiments demonstrate that Hes1 expres-
sion is sufficient to enhance NF-kB activity and this effect maps
upstream of IkBa degradation, IKK phosphorylation, and TAK1
activity. A significant portion of these effects can be attributed
to the suppression of CYLD expression by Hes1. In agreement
with this notion, we have identified CYLD as a direct target for
Hes1 repression. CYLD is a deubiquitinating enzyme that was
originally identified as a tumor suppressor and is mutated in
familial cylindromatosis (Bignell et al., 2000). More recently,
CYLD inhibition has been associated with other tumors such
as melanoma (Massoumi et al., 2009) and breast (Hutti et al.,
2009). Although previous to this report, there was no informa-
tion about an involvement of CYLD in leukemia, abnormalY65-5811. Error bars denote ± standard deviation.
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Figure 6. Hes1 Directly Represses CYLD Transcription in T-ALL
(A) Scheme of the CYLD promoter indicating the putative Hes1 binding sites.
(B) Detection of the CYLD PRO-2 Hes1 binding site by PCR using the indicated antibodies.
(C) Relative enrichment of the CYLD promoter quantified by qPCR from ChIP with anti-Hes1 antibody in Jurkat T-ALL cells transduced with scrambled or
Hes1-shRNA. Error bars denote ± standard deviation.
(D) Primary mouse lineage-negative bone marrow progenitors were transduced with the indicated lentivirus and colonies obtained from serial replating on
methylcellulose were counted every week.
(E) Representative FACS analysis from week 3 progenitors after 7 days on OP9-Dll1 stroma.
(F) EpiTYPER methylation analysis showing no significant hypermethylation of the CYLD promoter. Patient samples were analyzed using the EpiTYPER
Sequenom methylation assay. The heat map illustrates the range of methylation percentages, with red indicating 0% methylation and yellow indicating 100%
methylation. Numbers along the top indicate CpG dinucleotide, patient sample numbers are listed along the vertical axis (p denotes the identity of the patient
as presented in Figure 5A). Samples are run in duplicate. Two primers were run for each region. The positive control, IVD, has near 100% methylation, whereas
the negative control, WGA, is unmethylated.
See also Figure S6.
Cancer Cell
Notch-Induced Hes1 Represses CYLD in T-ALLlymphopoiesis in CYLD-deficient animals had been reported
(Reiley et al., 2006). This abnormal differentiation observed in
the CYLD-deficient mice was initially associated with a defect
in Lck kinase activation in response to TCR signaling, however
it was later demonstrated that CYLD is also responsible for
TAK1 deubiquitination resulting in the inactivation of the
NF-kB pathway in T-lymphocytes (Reiley et al., 2007). Other
well-characterized CYLD substrates that participate in the276 Cancer Cell 18, 268–281, September 14, 2010 ª2010 Elsevier InNF-kB signaling include TRAF2, Bcl3, and IKKg/NEMO. We
demonstrate here that CYLD expression is downregulated in
T-ALL cell lines and primary samples, and that knocking down
Hes1 expression in these cells results in increased CYLD levels
and attenuation of the NF-kB signaling. Interestingly, Hes1-
mediated suppression appears to be the preferred mode of
regulation as no inactivating mutations or CYLD promoter
hyper-methylation were detected in human T-ALL (data notc.
Figure 7. IKK In Vitro Silencing Affects the
Survival of Human T-ALL Cell Lines
Human T-ALL cell lines were treated with 100 mM
of control (Co) or NBD inhibitory peptide for 24 hr.
(A) Nuclear extract from treated and untreated
cells were isolated and checked for NF-kB-DNA
binding activity by EMSA. Untreated cells (Ø) are
also shown.
(B) Bar graph indicating the proportion of Annexin
V positive cells 24 hr after the NBD treatment.
Error bars denote ± standard deviation. (*p <
0.05; **p < 0.01 Student’s t test analysis).
(C) Caspase-3 activation as detected by FACS
with fluorogenic cell permeable active caspase
3-specific probe (Fam-DEVD-fmk) in three
representatives T-ALL lines 24 hr posttreatment.
All experiments shown in (A–C) were repeated at
least three times.
(D) Heat map showing changes in expression of
selected genes in response to NBD peptide
treatment.
See also Figure S7.
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Notch-Induced Hes1 Represses CYLD in T-ALLshown and Figure 6). We should also mention that CYLD
suppression of expression is by itself unlikely to account for
the initial NF-kB activation. Indeed, it is likely that basal NF-kB
stimulation is required and is provided by either Notch itself
(Vilimas et al., 2007) and/or the T cell receptor (TCR). We have
previously shown that T-ALL cells express the pre-TCR that
can activate constitutively the NF-kB pathway (Aifantis et al.,
2001; Davis et al., 2001; Mandal et al., 2005). It is thus conceiv-
able that the tumors have basal NF-kB activation and suppres-
sion of the negative regulator of the IKK complex (CYLD) further
boosts pathway activation.
Another important point made by our studies is that Notch/
Hes1 activation is targeting the canonical NF-kB pathway in
T-ALL. NEMO is a regulatory subunit of IKK complex, which
is responsible for activation of canonical NF-kB signaling
pathway. The T lineage-specific deletion of NEMO prevents
the generation of peripheral T cells due to apoptotic death
mature thymocyte (Schmidt-Supprian et al., 2003). Consistent
with this notion, silencing NEMO/IKKg was sufficient to inhibit
NF-kB activation in our animal model of ICN1-dependent
T-ALL and affect tumor growth and animal survival. Explain-
ing these effects, gene expression studies in IKK-inactivated
T-ALL cells suggested that genes involved in regulating cell
survival or apoptosis are targeted by canonical NF-kB signaling
in T-ALL. Although several survival genes have been shown
to be NF-kB targets, two of them, the anti-apoptotic Bcl2A1
and the pro-apoptotic Bcl2L11 (Bim), both members of the
BCL2 family, showed contrasting modes of regulation in
response to IKK silencing. Bcl2A1 appears to play a key role
in Notch-induced T-ALL. We have previously shown that
Bcl2A1 is overexpressed in T-ALL and that its silencing was
able to affect the survival of both Notch1 and Notch3 overex-Cancer Cell 18, 268–281, Sepressing T cell leukemia lines (Mandal
et al., 2005). We have also previously
shown that Bim is expressed in low
amounts in T cell leukemia and that
it controls early T cell death induction(Mandal et al., 2008), making this molecule a putative therapy
target.
Although the role of NF-kB in leukemogenesis has been
previously reported (Davis et al., 2001), several recent studies
in tumors as diverse as diffuse large B cell lymphoma (DLBCL)
(Compagno et al., 2009; Kato et al., 2009) or lung adenocarci-
noma (Compagno et al., 2009; Kato et al., 2009; Meylan et al.,
2009) suggest that the possibility to target this pathway in cancer
therapy should be re-evaluated. In agreement with our findings,
alterations in different elements of the NFkB pathway, including
the enzymes A20 and CYLD, were found to be responsible for
activating NF-kB in multiple myeloma and DLBCL, upstream of
the IKK complex (Annunziata et al., 2007; Compagno et al.,
2009; Kato et al., 2009; Keats et al., 2007; Lenz et al., 2008). In
lung cancer cells with mutated K-ras, NF-kB is activated by the
noncanonical TBK1/IKK interaction (Barbie et al., 2009) and
blocking IKK activity reduces tumor growth in vivo (Meylan
et al., 2009). We demonstrate here that in T-ALL, IKK can be
activated by the Notch-Hes1-CYLD signaling cascade. How-
ever, whatever the trigger, the outcome is identical: activation
of IKK, degradation of IkBa and nuclear translocation of the
NF-kB factor, which provides the base to consider that pharma-
cological targeting of the IKK/NF-kB pathway could be a prom-
ising future treatment of a wide spectrum of tumors. The recent
development of chemical inhibitors of the IKK complex, drugs
that are currently in clinical trials for inflammatory disease, will
enable us to test this hypothesis in future treatment protocols.
EXPERIMENTAL PROCEDURES
Mice and Animal Procedures
C57BL/6, or BALB/C mice were purchased from Jackson Laboratories and
Taconic Farms. BALB/C-Tg(NF-kB-RE-luc [Oslo]) were purchased fromptember 14, 2010 ª2010 Elsevier Inc. 277
Figure 8. The NEMO/IKK Complex Activity Is Essential for the Maintenance of T-ALL In Vivo
(A and B) Peripheral blood FACS analysis using CD4, CD8, and Ly5.2 antibodies at different time points posttransplantation.
(C)DEN1-luc Nemowt/wt,Mx-Cre andDEN1-luc Nemof/f,Mx-Cre chimeras were monitored before and after pI-pC injections using in vivo imaging system (IVIS) to
quantify luciferase intensity. Two weeks posttransplantation and before any deletion of NEMO, both chimeras harbored homogenous tumor load. Once this was
verified mice were injected by pI-pC.
(D) Quantification of luciferase intensity (dorsal and ventral) at different time points. Error bars denote ± standard deviation.
(E) Determination of apoptotic cells gated on GFP+ cells 5 days after pIpC injections inDEN1-GFP Nemowt/wt,Mx-Cre andDEN1-GFP Nemof/f,Mx-Cre chimeras.
(F) Micrographs of hematoxylin/eosin-stained liver and spleen sections prepared 40 days after transplantation.
(G) Kaplan-Meyer survival curve of the different recipient animals (p < 0.005).
See also Figure S8.
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Cancer Cell
Notch-Induced Hes1 Represses CYLD in T-ALLCaliper. Nemof/f mice have been described previously (Schmidt-Supprian
et al., 2000). Cyld knockout mice were generated as described previously
(Reiley et al., 2007). For the polyI-polyC experiments, we injected 20 mg
pI-pC (Amersham) per gram of body weight. All mice were kept in specific
pathogen-free animal facilities. All animal procedures were approved by and
carried out in accordance to the guidelines of the Institutional Animal Care
and Use Committee of the New York University-School of Medicine.Human T-ALL Samples
A total of 33 T-ALL samples and normal blood samples were obtained from the
Hematology Department of Hospital de Sant Pau and the Department of
Pathology of Hospital del Mar, Barcelona, Spain. All patients gave written
consent to donate the blood specimen. The study was approved by the Ethics
Committee of the Institution (Department of Pathology, Hospital del Mar).Plasmids
3xkB-luciferase and HA-IkBaS32–36A (Espinosa et al., 2003), IkBaK21-22R
(Arenzana-Seisdedos et al., 1997), HA-TAK1K63W (Ninomiya-Tsuji et al.,
1999), DEN1-Luciferase, DEN1-GFP and ICN1-GFP retroviral constructs
(Chiang et al., 2006; Vilimas et al., 2007), or ICN1DOP (Bigas et al., 1998)
have been previously described. Flag-Hes1 was obtained from M. Caudy
(Castella et al., 1999) and used to clone Hes1 cDNA into the inducible vector
pcDNA3.TO. pTHR1-NF-kB-dscGFP and pTHR1-mCMV-dscGFP lentiviral
constructs were purchased from System Biosciences. CYLD retroviral and
shRNA constructs were given by A. Pfeifer (Massoumi et al., 2009). Human
and mouse-specific Hes1-shRNA lentiviral constructs was purchased from
Sigma (TRCN0000018989 and TRCN0000028854, respectively).Bioluminescence Imaging
Imaging of kB-ER-luciferase and DEN1-luciferase chimeras were carried out
as previously described (Tseng et al., 2006).qRT-PCR and Microarray
The primers used for RT-PCR analysis are listed in the Supplemental
Experimental Procedures. qRT-PCRwas carried out in LightCycler480 system
using SYBR Green I Master or Probes Master kit (Roche). For microarray
analysis, the data set of the genome-wide RNA expression analyses of human
T-ALL cells lines treated by control peptide versus NBD peptide has been
deposited in the Gene Expression Omnibus database (http://www.ncbi.nlm.
nih.gov/geo/); the accession number is GSE20667. RNA was labeled on
hybridized to the Human U133 Plus 2.0 microarray (Affymetrix). The Affymetrix
gene expression profiling data was first normalized using previously published
robust multi-array average (RMA) algorithm implemented in RNAExpress soft-
ware version 1.0.4 (http://rmaexpress.bmbolstad.com/) and log2 transformed.
Then genes that are differentially expressed betweenNBDpeptide treated and
control peptide treated cells were selected using a paired two-side t test and
requiring fold change R1.2 or %0.833. The multiple comparison correction
was carried out using the approach of (Reiner et al., 2003) with FDR threshold
equal to 0.10. The application of the above procedure resulted in 387 genes
(531 oligonucleotide probes).Quantitative DNA Methylation Analysis
DNA methylation analysis was carried out using the EpiTYPER system from
Sequenom (San Diego, CA). The EpiTYPER assay is a tool for the detection
and quantitative analysis of DNA methylation using base-specific cleavage
of bisulfite-treated DNA and matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS). Specific PCR primers for
bisulfite-converted DNA were designed using the EpiDesigner software
(www.epidesigner.com), for the entire CpG island of the genes of interest.
T7-promoter tags are added to the reverse primer to obtain a product that
can be in vitro transcribed, and a 10-mere tag is added to the forward primer
to balance the PCR conditions. Primer sequences, target chromosomal
sequence, and EpiTYPER-specific tags, are available on request. A detailed
description of the protocol used can be found at the Supplemental Experi-
mental Procedures.CanStatistical Analysis
Student’s t test was carried out to assess the significance of expression levels.
These data are presented as mean ± SD.
ACCESSION NUMBERS
Gene expression data are available in the Gene Expression Omnibus database
with the accession numbers GSE12948 and GSE20667.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two tables, and eight figures and can be found with this article online at
doi:10.1016/j.ccr.2010.08.006.
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